BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33333121)

  • 21. Application of CRISPR/Cas9 Technology to HBV.
    Lin G; Zhang K; Li J
    Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR based targeted genome editing of Chlamydomonas reinhardtii using programmed Cas9-gRNA ribonucleoprotein.
    Dhokane D; Bhadra B; Dasgupta S
    Mol Biol Rep; 2020 Nov; 47(11):8747-8755. PubMed ID: 33074412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
    Liu X; Hao R; Chen S; Guo D; Chen Y
    J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulating CRISPR-Cas Genome Editing Using Guide-Complementary DNA Oligonucleotides.
    Swartjes T; Shang P; van den Berg DTM; Künne T; Geijsen N; Brouns SJJ; van der Oost J; Staals RHJ; Notebaart RA
    CRISPR J; 2022 Aug; 5(4):571-585. PubMed ID: 35856642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C; Lu M; Yang D
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
    Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
    Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome Editing.
    Li B; Zeng C; Li W; Zhang X; Luo X; Zhao W; Zhang C; Dong Y
    Cell Rep; 2018 Dec; 25(12):3262-3272.e3. PubMed ID: 30566855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome editing using preassembled CRISPR-Cas9 ribonucleoprotein complexes in Fusarium graminearum.
    Lee N; Park J; Kim JE; Shin JY; Min K; Son H
    PLoS One; 2022; 17(6):e0268855. PubMed ID: 35657788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.
    Wang D; Chen L; Li C; Long Q; Yang Q; Huang A; Tang H
    J Nanobiotechnology; 2022 Jan; 20(1):27. PubMed ID: 34991617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.
    Soares Medeiros LC; South L; Peng D; Bustamante JM; Wang W; Bunkofske M; Perumal N; Sanchez-Valdez F; Tarleton RL
    mBio; 2017 Nov; 8(6):. PubMed ID: 29114029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.
    Taha EA; Lee J; Hotta A
    J Control Release; 2022 Feb; 342():345-361. PubMed ID: 35026352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing.
    Manghwar H; Lindsey K; Zhang X; Jin S
    Trends Plant Sci; 2019 Dec; 24(12):1102-1125. PubMed ID: 31727474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing.
    Chen G; Abdeen AA; Wang Y; Shahi PK; Robertson S; Xie R; Suzuki M; Pattnaik BR; Saha K; Gong S
    Nat Nanotechnol; 2019 Oct; 14(10):974-980. PubMed ID: 31501532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insertional Mutagenesis by CRISPR/Cas9 Ribonucleoprotein Gene Editing in Cells Targeted for Point Mutation Repair Directed by Short Single-Stranded DNA Oligonucleotides.
    Rivera-Torres N; Banas K; Bialk P; Bloh KM; Kmiec EB
    PLoS One; 2017; 12(1):e0169350. PubMed ID: 28052104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR/Cas9: at the cutting edge of hepatology.
    Pankowicz FP; Jarrett KE; Lagor WR; Bissig KD
    Gut; 2017 Jul; 66(7):1329-1340. PubMed ID: 28487442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells.
    Lin Y; Wilk U; Pöhmerer J; Hörterer E; Höhn M; Luo X; Mai H; Wagner E; Lächelt U
    Small; 2023 Jan; 19(2):e2205318. PubMed ID: 36399647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric oligonucleotides combining guide RNA and single-stranded DNA repair template effectively induce precision gene editing.
    Ghosh A; Myacheva K; Riester M; Schmidt C; Diederichs S
    RNA Biol; 2022; 19(1):588-593. PubMed ID: 35465826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
    Li S; Song Z; Liu C; Chen XL; Han H
    ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.
    Bykonya AG; Lavrov AV; Smirnikhina SA
    Mol Biotechnol; 2023 Feb; 65(2):181-195. PubMed ID: 35322386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.